Patents Assigned to Ascendis Pharma Growth Disorders Division A/S
  • Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier
    Publication number: 20170056477
    Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.
    Type: Application
    Filed: November 1, 2016
    Publication date: March 2, 2017
    Applicant: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
  • Dry growth hormone composition transiently linked to a polymer carrier
    Patent number: 9511122
    Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: December 6, 2016
    Assignee: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
  • PEGylated Recombinant Human Growth Hormone Compounds
    Publication number: 20160206702
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Application
    Filed: January 19, 2016
    Publication date: July 21, 2016
    Applicant: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • PEGylated recombinant human growth hormone compounds
    Patent number: 9272048
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: March 1, 2016
    Assignee: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Harald Rau, Susanne Kinderman, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe